The COSMOS trial
The Cocoa Supplement and Multivitamin Outcomes Study
The COSMOS trial is designed to determine whether daily supplements of cocoa flavanols or a common multivitamin reduce the risk of developing heart disease, stroke, and cancer.
COSMOS trial snapshot
- Investigator-initiated clinical dietary intervention
- Randomized, double-blind, placebo-controlled
- Large-scale and long-term involving over 21,000 generally healthy men and women in the US
- Run by Brigham and Women’s Hospital
The trial is a large-scale, five-year clinical dietary intervention involving over 21,000 generally healthy men and women aged 60 years and older, from across the U.S. COSMOS is a randomized, double-masked, placebo-controlled dietary intervention trial, based on hard endpoints: cardiovascular morbidity and mortality.
The trial investigates the impact of consuming daily 500 mg of cocoa flavanols (80 mg of (–)-epicatechin) delivered via a cocoa extract-based supplement over a four-year period.
COSMOS is being run by Brigham and Women’s Hospital, an affiliate of Harvard Medical School, and the Fred Hutchinson Cancer Research Center. Mars Edge is providing funding for COSMOS and the cocoa flavanol test materials. We have also provided scientific input on specific elements of the study and enabled ancillary trial elements that expand the range of data and insights that can be obtained from the COSMOS trial.
There is growing body of research indicating that cocoa flavanols can support health. Our latest research papers found that increased flavanol intake is linked to improved memory in adults and consuming a diet including flavanol-rich foods could lead to lower blood pressure. COSMOS will provide further insights into whether these benefits may be sustained over a longer period.
Its specific ancillary trial design element, the trial is also set to provide significant scientific data on healthy aging, cognition, metabolic health, eye health and gut health. The outcomes of COSMOS will become available in late 2021